Q2 2025 · 13F-HR
Rosalind Advisors, Inc.holdings as filed
Filed 2025-08-14 · accession 0001622627-25-000028
$210.9M
Reported value
37
Positions
2025-06-30
Period end
The Brief · Rosalind Advisors, Inc. · Q2 2025
AI · grounded in 13F
Rosalind Advisors, Inc. established a new position in DCTH valued at $33.0M. The fund also initiated new stakes in FENC for $16.9M and CYTK for $13.2M. Additional new positions include OCUL at $11.3M and IDYA at $10.7M. Total assets under management stand at $210.8M across 37 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 24661P807 | DCTH | DELCATH SYS INC | $33.0M | 15.6% | 3,300,389 | Common | SOLE |
| 31447P100 | FENC | FENNEC PHARMACEUTICALS INC | $17.0M | 8.05% | 2,045,644 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $13.2M | 6.27% | 400,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $11.3M | 5.36% | 1,218,700 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $10.7M | 5.09% | 511,132 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $10.1M | 4.77% | 2,155,594 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $9.8M | 4.64% | 700,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $9.5M | 4.48% | 100,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $8.5M | 4.02% | 2,043,563 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $8.4M | 3.96% | 900,000 | Common | SOLE |
| M68830112 | MDWD | MEDIWOUND LTD | $7.9M | 3.74% | 407,061 | Common | SOLE |
| 62857J201 | MYO | MYOMO INC | $7.8M | 3.68% | 3,595,788 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $7.8M | 3.68% | 1,741,211 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $7.4M | 3.52% | 542,366 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $6.8M | 3.23% | 810,918 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $6.1M | 2.87% | 2,654,944 | Common | SOLE |
| 45779A846 | NSPR | INSPIREMD INC | $5.2M | 2.46% | 2,289,099 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $5.0M | 2.38% | 192,974 | Common | SOLE |
| 74319B502 | PROF | PROFOUND MED CORP | $4.1M | 1.94% | 692,185 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $3.9M | 1.87% | 223,627 | Common | SOLE |
| M8001Q126 | PYPD | POLYPID LTD | $3.4M | 1.63% | 975,462 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $2.7M | 1.29% | 420,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $1.8M | 0.85% | 157,725 | Common | SOLE |
| 45782T955 | INMB | INMUNE BIO INC | $1.8M | 0.84% | 1,033,200 | PUT | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $1.6M | 0.78% | 300,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.4M | 0.64% | 482,651 | Common | SOLE |
| 00444T209 | TLPH | TALPHERA INC | $922,212 | 0.44% | 2,003,939 | Common | SOLE |
| 09077D209 | BFRI | BIOFRONTERA INC | $694,742 | 0.33% | 976,448 | Common | SOLE |
| M96088905 | URGN | UROGEN PHARMA LTD | $600,000 | 0.28% | 100,000 | CALL | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $577,000 | 0.27% | 100,000 | Common | SOLE |
| 78464A950 | — | SPDR SERIES TRUST | $534,000 | 0.25% | 550,000 | PUT | SOLE |
| 76029N906 | REPL | REPLIMUNE GROUP INC | $515,650 | 0.24% | 231,800 | CALL | SOLE |
| 78462F953 | SPY | SPDR S&P 500 ETF TR | $432,500 | 0.21% | 250,000 | PUT | SOLE |
| 002120952 | ATYR | ATYR PHARMA INC | $271,050 | 0.13% | 223,000 | PUT | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $164,950 | 0.08% | 500,000 | Common | SOLE |
| 45166A902 | IDYA | IDEAYA BIOSCIENCES INC | $68,000 | 0.03% | 20,000 | CALL | SOLE |
| 22663K907 | CRNX | CRINETICS PHARMACEUTICALS IN | $57,970 | 0.03% | 52,700 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.